Evaxion biotech announces closing of $27.6 million follow-on public offering, including full exercise of the underwriters' option to purchase additional shares

Copenhagen, denmark, nov. 09, 2021 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today the closing of its follow-on public offering of 3,942,856 american depositary shares ("adss"), at a public offering price of $7.00 per ads, which includes the exercise in full of the underwriters' option to purchase 514,285 additional adss, with each such ads representing one ordinary share, dkk 1 nominal value per share, of evaxion (the "ordinary shares"). the gross proceeds to the company from the offering were approximately $27.6 million before deducting underwriting fees, commissions and other offering expenses. the company's adss are listed on the nasdaq capital market in the united states and the adss trade under the symbol "evax". all adss were offered by the company.
EVAX Ratings Summary
EVAX Quant Ranking